ClinicalTrials.gg

Program

AZD9550

A development code. Also written as “AZD9550 solution for injection”, “AZD9550 and AZD6234” and “AZD6234 in combination with AZD9550”.

Its studies are mostly in Obesity · Lymphoma, Follicular · Non-alcoholic Fatty Liver Disease, led by AstraZeneca.

Furthest: phase 2, since Sep 22, 20237 company-led studies, 5 open or runningNext primary completion: Jan 29, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca75 open or runningphase 2since Sep 22, 2023Mar 31, 2023Jan 29, 2027phase 2 · NCT06151964
  • Named in AstraZeneca’s own pipeline as AZD9550, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: quotient-sciences and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2023First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05848440 · 48 enrolled · United Kingdom
  2. Sep 22, 2023Phase 2 study in OverweightNCT06151964 · 166 enrolled · Austria, Canada, Germany and more
  3. Feb 14, 2025Phase 2 study in ObesityNCT06862791 · 377 enrolled · United States, Australia, Canada and more
  4. May 14, 2025Phase 2 study in ObesityNCT07017179 · 16 enrolled · China
  5. Jun 2, 2025Phase 1 study in ObesityNCT07013643 · 100 enrolled · United States
  6. Mar 11, 2026Phase 1 study in Lymphoma, FollicularNCT07546760 · 28 planned · United States
  7. Sep 29, 2026Primary completion moved from 2026-08-06 to 2026-10-23Date moved laterphase 2 · +3 months · NCT07017179
  8. Oct 26, 2026Phase 1 study in ObesityNCT07911514 · 60 planned · United Kingdom

Ahead

  1. Jan 29, 2027Primary completion: phase 2 study in OverweightNCT06151964
  2. Feb 4, 2027Primary completion: phase 1 study in Lymphoma, FollicularNCT07546760
  3. May 4, 2027Primary completion: phase 1 study in ObesityNCT07911514
  4. Jul 9, 2027Primary completion: phase 1 study in ObesityNCT07013643

TargetBeta

“AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist.”study summary, read by Claude · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
DR10624ruleHuadong Medicinephase 36
efinopegdutideJohnson & Johnsonphase 215
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911514Obesity · United Kingdom1Not yet recruitingMay 4, 202760
NCT07546760Lymphoma, Follicular · United States1RecruitingFeb 4, 202728
NCT07013643Obesity · United States1Active, not recruitingJul 9, 2027100
NCT07017179Obesity · China2Active, not recruitingOct 23, 202616
NCT06862791Obesity · United States, Australia, Canada and more2CompletedMay 11, 2026377
NCT06151964Overweight · Austria, Canada, Germany and more2Active, not recruitingJan 29, 2027166
NCT05848440Non-alcoholic Fatty Liver Disease · United Kingdom1CompletedNov 13, 202348

How it is read

Names in the registry

  • “AZD9550”, 7 entries
  • “AZD9550 solution for injection”, 1 entry
  • “AZD9550 and AZD6234”, 1 entry
  • “AZD6234 in combination with AZD9550”, 1 entry

Codes read as this program: AZD9550.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.